[1]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662-665.[doi:10.3969/j.issn.1004-3934.2015.06.002]
 CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(6):662-665.[doi:10.3969/j.issn.1004-3934.2015.06.002]
点击复制

钙通道阻滞剂在降压治疗中的应用()
分享到:

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
662-665
栏目:
主题综述
出版日期:
2016-06-20

文章信息/Info

Title:
Application of Calcium Channel Blockers in Hypertension Treatment
作者:
陈源源
北京大学人民医院心脏中心,北京 100044
Author(s):
CHEN Yuanyuan
Heart Centre,Peking University People's Hospital,Beijing 100044,China
关键词:
高血压 钙通道拮抗剂 钙离子通道亚型 心血管保护
Keywords:
hypertension calcium channel blockers subtype calcium channel cardiovascular protection
分类号:
R544.1; R972+.4
DOI:
10.3969/j.issn.1004-3934.2015.06.002
文献标志码:
A
摘要:
钙通道阻滞剂通过阻滞动脉血管平滑肌细胞上的钙通道,降压疗效明确,适用于几乎所有类型的高血压患者。依据钙通道阻滞剂与动脉血管及心脏的亲和力不同,以及钙通道阻滞剂与钙离子通道亚型的亲和力不同,钙通道阻滞剂有效降压及全面心血管保护作用各有千秋。
Abstract:
By blocking the smooth muscle cell's calcium channel at arteries, calcium channel blockers(CCB)can reduce blood pressure effectively and reliably. According to the affinity of CCB on artery or heart, and on the basis of affection at subtype calcium channel, different CCBs have their own advantages on anti-hypertensive effects and cardiovascular protection.

参考文献/References:

[1] Hayashi K, Wakino S, Sugano N,et al.Ca2+channel subtypes and pharmacology in the kidney[J].Circ Res,2007,100:342-353.
[2] 薛全福,王振纲. 钙通道不同分型与亚基和抗高血压药物的关系[J]. 中国药理学通报,2008,24(5):569-572.
[3] 中国高血压防治指南修订委员会. 中国高血压防治指南2010[J]. 中国医学前沿杂志:电子版,2011,3(5):42-93.
[4] Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment(INSIGHT)[J]. Lancet,2000,356:366-372.
[5] Lubsen J, Wagener G, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial[J]. J Hypertens,2005,23:641-648.
[6] Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment(ACTION trial): randomized controlled trial[J]. Lancet,2004,364:849-857.
[7] Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial[J]. Lancet,2004,363:2022-2031.
[8] Dahlöf B, Sever PS, Poulter NR,et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm(ASCOT-BPLA): a multicentre randomised controlled trial[J]. Lancet, 2005,366:895-906..
[9] Weber MA, Bakris GL, Dahlof B, et al. Baseline characteristics in the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension(ACCOMPLISH)trial: a hypertensive population at high cardiovascular risk[J]. Blood Press,2007,16:13-19.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
 SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
 FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(6):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
 ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[4]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
 ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[5]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
 HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(6):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[6]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
 ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(6):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[7]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[8]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
 LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(6):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[9]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
 WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(6):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
[10]付士辉李玉龙骆雷鸣沈明志田进文邓珏琳.高血压基础研究现状与进展[J].心血管病学进展,2019,(9):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]
 FU ShihuiLI YulongLUO LeimingSHEN MingzhiTIAN JinwenDENG Juelin.Status and Progress of Basic Researches about Hypertension[J].Advances in Cardiovascular Diseases,2019,(6):1202.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.004]

备注/Memo

备注/Memo:
作者简介:陈源源(1961—),主任医师,硕士,主要从事高血压、心脑血管疾病防治研究。Email:yuanyuandao@sina.com
更新日期/Last Update: 2016-06-20